May. 8 at 7:16 PM
$AGEN It depends on what you are trying to do:
* If you are looking for a high-risk biotech trade with potentially massive upside, AGEN is interesting.
* If you are looking for a safer long-term investment, it is still very speculative.
Why people are buying it:
* BOT/BAL may be one of the first real immunotherapy breakthroughs in MSS colorectal cancer.
* Phase 3 is now underway globally.
* Survival data so far is legitimately impressive for this disease:
* ~21-month median OS
* 42% two-year survival in selected patients.
* FDA aligned with the Phase 3 path, which matters a lot.
* If BOT/BAL works in Phase 3, the valuation could potentially be many multiples higher than today.
But the risks very real:
* Small biotech companies fail all the time.
* Phase 3 oncology trials often disappoint versus early data.
* Agenus has historically burned cash heavily.
* The company is basically betting the future on BOT/BAL.
* If Phase 3 fails, the stock could collapse hard.
